| |
| |
|
| Insider
Information: |
Aryeh Jason |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
401,047 |
|
|
Indirect Shares
|
890,847 |
|
|
| Direct
Value |
$7,148,144 |
|
|
|
Indirect Value
|
$4,945,268 |
|
|
| Total
Shares |
1,291,894 |
|
|
| Total
Value |
$12,093,412 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Director |
2024-04-30 |
76,828 |
2024-04-30 |
56,619 |
Premium* |
|
|
Vaxart Inc |
VXRT |
Director |
2010-12-27 |
0 |
2011-03-15 |
131,783 |
Premium* |
|
|
Myrexis Inc |
MYRX |
Director |
|
0 |
2012-06-15 |
552,145 |
Premium* |
|
|
Novelion Therapeutics Inc |
NVLN |
Director |
2017-05-15 |
242,433 |
2017-05-15 |
150,300 |
Premium* |
|
|
Aralez Pharmaceuticals Inc. |
ARLZ |
Director |
2017-05-23 |
15,000 |
2017-05-23 |
0 |
Premium* |
|
|
Merrimack Pharmaceuticals Inc |
MACK |
See Explanation of Res... |
2019-07-16 |
3,802 |
2019-07-11 |
0 |
Premium* |
|
|
Orchestra BioMed Holdings Inc. |
OBIO |
Director |
2023-04-12 |
62,984 |
2023-01-26 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
175 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 2 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2011-03-16 |
4 |
B |
$9.25 |
$37,405 |
I/I |
4,000 |
276,611 |
2.1 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2011-05-12 |
4 |
B |
$10.96 |
$18,906 |
I/I |
1,725 |
281,336 |
2.1 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2011-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,372 |
21,801 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2011-08-10 |
4 |
B |
$10.57 |
$21,140 |
I/I |
2,000 |
283,336 |
2.1 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2011-11-10 |
4 |
B |
$10.90 |
$21,910 |
I/I |
2,000 |
5,025 |
2.1 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2012-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
6,517 |
28,318 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2012-06-01 |
4 |
B |
$11.98 |
$8,386 |
I/I |
700 |
285,036 |
2.1 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2013-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,925 |
31,243 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2014-02-12 |
4 |
S |
$75.21 |
$1,814,121 |
I/I |
(24,120) |
260,916 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2014-02-13 |
4 |
S |
$77.43 |
$518,779 |
I/I |
(6,700) |
254,216 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2014-02-14 |
4 |
S |
$78.87 |
$749,265 |
I/I |
(9,500) |
244,716 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
INSIDER |
– – – |
2014-02-18 |
144 |
NP |
$0.00 |
$3,091,664 |
/ |
40,320 |
0 |
|
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2014-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
1,817 |
33,060 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2014-09-25 |
4 |
OE |
$6.82 |
$236,584 |
D/D |
20,300 |
53,360 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2014-10-01 |
4 |
OE |
$32.30 |
$236,920 |
D/D |
7,335 |
60,695 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2014-10-09 |
4 |
B |
$42.99 |
$472,890 |
I/I |
11,000 |
255,716 |
2.1 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2014-12-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,283 |
57,412 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2015-04-24 |
4 |
A |
$0.00 |
$0 |
D/D |
925 |
58,337 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2015-05-18 |
4 |
S |
$86.74 |
$520,440 |
I/I |
(6,000) |
249,716 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2015-05-19 |
4 |
S |
$88.82 |
$198,957 |
I/I |
(2,240) |
247,476 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2015-05-20 |
4 |
S |
$87.65 |
$87,650 |
I/I |
(1,000) |
246,476 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2015-06-04 |
4 |
S |
$92.68 |
$151,995 |
I/I |
(1,640) |
244,836 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2015-11-11 |
4 |
S |
$101.49 |
$304,470 |
I/I |
(3,000) |
241,836 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2016-03-07 |
4 |
S |
$101.07 |
$568,895 |
I/I |
(5,629) |
236,207 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2016-03-08 |
4 |
S |
$102.49 |
$51,245 |
I/I |
(500) |
235,707 |
0 |
- |
|
175 Records found
|
|
Page 2 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
